MaxCyte Files 8-K on Operations and Financials

TL;DR

MaxCyte filed an 8-K updating investors on its financials and operations.

AI Summary

MaxCyte, Inc. filed an 8-K on March 5, 2024, reporting on its results of operations and financial condition as of March 4, 2024. The filing includes financial statements and exhibits, but does not provide specific financial figures or operational details within the provided text.

Why It Matters

This 8-K filing indicates MaxCyte is providing updates on its financial condition and operational results to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant negative events.

Key Players & Entities

• MAXCYTE, INC. (company) — Registrant
• March 4, 2024 (date) — Earliest event reported
• March 5, 2024 (date) — Filing date
• 9713 Key West Avenue, Suite 400 (address) — Principal executive offices
• Rockville, Maryland 20850 (address) — Principal executive offices location

FAQ

Key Financial Figures

• $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar

Filing Documents

• mxct-20240304x8k.htm (8-K) — 37KB
• mxct-20240304xex99d1.htm (EX-99.1) — 34KB
• mxct-20240304xex99d1001.jpg (GRAPHIC) — 7KB
• 0001558370-24-002480.txt ( ) — 206KB
• mxct-20240304.xsd (EX-101.SCH) — 3KB
• mxct-20240304_lab.xml (EX-101.LAB) — 16KB
• mxct-20240304_pre.xml (EX-101.PRE) — 10KB
• mxct-20240304x8k_htm.xml (XML) — 5KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On March 4, 2024, MaxCyte, Inc. (the " Company ") issued a press release announcing preliminary financial results for the quarter and fiscal year ended December 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instructions B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated March 4, 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: March 5, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR